Get Started in3 Simple Steps
Postmenopausal women experience a two- to three-fold increase in cardiometabolic risk, underscoring the need for targeted interventions. (Mauvais-Jarvis et al., 2017) Not All GLP-1 Agonists Are the Same Todays GLP-1 therapies vary in structure, receptor affinity, and clinical profile, and these nuances may matter for midlife women: Exenatide (Byetta, Bydureon): Derived from Gila monster venom peptide
Neurons and astrocytes respond to prion infection by inducing microglia recruitment
Symptoms such as intense abdominal pain, nausea paired with vomiting, rapid heartbeat, and even yellowing skin or eyes demand immediate medical intervention
Even peptides with short half-lives can leave metabolic traces in the body that trigger a positive result on advanced panels
Self-administration of such products is strongly discouraged and may carry serious health consequences